Webinars

PELOAcademy | A new threat in Cell Culture: Cross-Contamination of Cell Lines

Presented by Prof. Dr. Gerhard Gstraunthaler, Institut für Physiologie der Medizinischen Universität Innsbruck, emer

Cross-contamination is the erroneous contamination of a given culture with unrelated cells of another cell line, either from the same species (intra-species contamination) or with cells from another species (inter-species contamination).

When the contaminant is a rapidly dividing cell line (e.g., HeLa cells), it can overgrow and replace the original cell culture very soon, within a few passages. In earlier times, due to the widespread use of animal cell lines, inter-species contaminations were most common.

PELOAcademy | Scalable EV Isolation and High-Quality Purification with Advanced Technologies

Presented by Prof. Dr. Sehyun Shin, Korea University & CEO, Microgentas Inc., Seoul, Korea

Learn about innovative approaches for scalable EV isolation and high-quality purification, focusing on the integration of charge-based filtration (ExoFilter) with other technologies like TFF and LipoFilter. Learn how ExoFilter, combined with Tangential Flow Filtration (ExoTFF), and the lipoprotein-specific LipoFilter, optimize EV yield and purity.

Cardiosight®-S exhibits a purity exceeding 95% of cardiac markers and demonstrates a dose-dependent response to drugs targeting electrophysiological ion channels, suggesting high physiological relevance of the cells.

PELOAcademy | Compatibility of hiPSC-derived cardiomyocytes in cardiac safety assessment of drugs

Presented by Jieun An, Ph.D., Senior scientist, NEXEL Co, Seoul, Korea

We introduce NEXEL’s Cardiosight®-S (hiPSC-CMs), aligning with the updated ICH E14/S7B guidelines, and provide practical examples of its applications. Cardiosight®-S exhibits a purity exceeding 95% of cardiac markers and demonstrates a dose-dependent response to drugs targeting electrophysiological ion channels, suggesting high physiological relevance of the cells.

PELOAcademy | Humanized Multi-Organoid Disease Models Advancing 3D drug development models

Presented by Dr. Raquel Sousa, Research and Development Scientist, abc biopply, Switzerland

Traditional in vitro and in vivo disease models have demonstrated significant limitations in accurately predicting patient responses to treatment. Efforts have been made to humanize mouse models in order to better reflect aspects of human physiology and immunology, these attempts have had limited success. Learn about the breakthrough in humanizing 3D cell models through the 3D CoSeedis multi-organoid in-chip technology™.

Isolation of Cells from Fat_60th Anniversary of Martin Rodbell's Seminal Publication

Presented by Stuart K. Williams, PhD, University of Louisville, Scottsdale, Arizona, USA

Explore the evolution of methods for isolating adipocytes and adipose-derived stromal vascular fraction (ADSVF) cells. Factors responsible for the variability in ADSVF cells include species and anatomic differences in fat tissue, mincing, tissue dissociation enzymes, agitation, filtration, and centrifugation. Technologies used to characterize these cells will also be discussed, including cell counting, viability, and cellular markers.

Collagenase Selection & Process Optimization for High Yield Hepatocyte Isolation

Presented by Rafal Witek, Senior Director of R&D Engineering, Dimension Inx, USA, and our partner VitaCyte, USA

This webinar reviews best practices for building a high-yield primary human and animal hepatocyte isolation process with the inclusion of collagenase selection and buffer optimization. The webinar will cover process variabilities that impact isolation and how to overcome them to generate high-quality and high-viability hepatocytes. The information presented will enable participants to build their isolation, resulting in a high success rate and hepatocyte yield.

PELOAcademy | Adipocyte spheroids: Obesity-related Research in a more in vivo-like Environment

Presented by Dr. rer. nat. Anita Wagner, Chair of Molecular Nutritional Medicine, Technical University of Munich

Utilizing a three-dimensional environment to cultivate adipocytes is a method that more accurately replicates in vivo conditions compared to conventional two-dimensional cultures. This valuable computational tool can be employed to analyze dynamic interactions within the WAT microenvironment, offering insights into adipose tissue biology and identifying potential therapeutic targets for metabolic disorders.

EMERGE Epsiode 19 | Deep proteomic insight into disease biology identifies age-specific vulnerabilities in acute leukemia

Presented by Sudip Ghosh, Lund Stem Cell Center, Lund University, Sweden and Resyn Biosciences, South Africa

Infant and adult MLL1/KMT2A-rearranged (MLLr) leukemia represents a disease with a dismal prognosis. We revealed early proteomic events of MLL::ENL-mediated transformation in fetal and adult blood progenitors. Adult pre-leukemic cells are mainly characterized by retained myeloid features and downregulation of ribosomal and metabolic proteins, expression of MLL::ENL in fetal lymphomyeloid multipotent progenitors (LMPPs) leads e.g. to the enrichment of translation-associated and histone deacetylases signaling proteins.

EMERGE Epsiode 18 | Systematic optimization of automated phosphopeptide enrichment for high-sensitivity phosphoproteomics

Presented by Patricia Bortel, BSc, MSc, Institut für Analytische Chemie Wien, and hosted by ReSyn, South Africa

Improving coverage, robustness, and sensitivity is crucial for routine phosphoproteomics analysis by single-shot liquid chromatography tandem mass spectrometry (LC-MS/MS) from minimal peptide input. The webinar focuses on the systematic optimization of key experimental parameters for automated on-bead phosphopeptide sample preparations, low-input samples, pinpointing critical variables influencing the resulting phosphoproteome coverage.

EMERGE Epsiode 17 | Streamlined proteome-wide identification of drug targets indicates organ-specific engagement

Presented by Tanveer Batth, Novo Nordisk, Center for Protein Research, Danmark and ReSyn Biosciences, South Africa

Proteins are the primary targets of almost all small-molecule drugs. Even drugs designed with high specificity may interact with multiple proteins that are not initially targeted. Discovering these potential interactions is crucial for the development and repurposing of drugs. We report the development of a label-free quantitative proteomics approach that enables proteome-wide screening of small organic molecules in a scalable, reproducible, and rapid manner by streamlining the proteome integral solubility alteration (PISA) assay. Tanveer is a researcher at the NNF CPR in Denmark.

EMERGE Episode 16 | The potential of plasma HLA peptides beyond neoepitopes

Presented by Maria Wahle, PhD student, Max-Planck-Institute of Biochemistry, Munich and and ReSyn Biosciences, South Africa

Soluble HLA (sHLA) peptides are thought to have great potential as biomarkers for different diseases such as cancer. However, efficient enrichment of sHLA peptides from body fluids like plasma has been a bottleneck, requiring 3-5 ml per patient. Maria presents IMBAS-MS, an automated magnetic bead-based workflow for the efficient enrichment of HLA protein-peptide complexes. The core of IMBAS-MS is the combination of biotinylated antibodies immobilized on streptavidin magnetic beads allowing for an automated one-pot enrichment from only 200 µl of plasma.

Islet Isolation Success of Chronic Pancreatitis Pancreas & Brain-Dead Donor Pancreas Intended for Auto & Allo-Transplantation

Presented by Balamurugan N. Appakalai, PhD, Nationwide Children’s Hospital and hosted by VitaCyte, Indianapolis, USA

Recovery of human islets from pancreata recovered from brain-dead donors and chronic pancreatitis patients for subsequent transplantation requires consideration of different factors. Isolating islets from pancreata from donors with a high BMI has a higher probability of success than isolating islets from donors with a low BMI. The choice of neutral protease and control of the ratio of collagenase/protease activities is critical since it affects the percentages of free and embedded islets.

PELOAcademy | Engineering Cardiac Microtissues for Cell Therapy

Presented by Dr. Kurt Pfannkuche, PD, The Marga-and-Walter-Boll-Laboratory for Cardiac Tissue Engineering, University of Cologne

Induced pluripotent stem cells (iPSCs) can be differentiated into heart muscle cells in vitro and open up new possibilities for the development of therapies for myocardial infarction. However, the transplantation of pure cardiac muscle cells from iPSCs has the disadvantage that only a small proportion of the cells remain in the tissue. The presentation will show approaches for the experimental production of cardiac microtissues for cell therapy.

Please ask for details e.g. the recording via email to anne.osman@PELOBiotech.com or come to the Conference on June 27 to meet Dr. Pfannkuche face-to-face.

PELOAcademy | From our Lab: Exploring the Advantages of Animal Component-Free Media in Cell Culture

Presented by Anna Lena Schuhmacher, University of Applied Sciences, Weihenstephan & Dr. Lothar Steeb, CSO&CEO PELOBiotech

We compare traditional animal component-based media with the emerging animal component-free alternatives. This webinar will provide an in-depth analysis of the benefits and potential challenges associated with animal component-free media, including considerations such as cell growth, viability, functionality, and downstream applications.

PELOAcademy | Stem Cell Culture: Differences, Properties, Prospects, Applications

Presented by Prof. Dr. Gerhard Gstraunthaler, Institut für Physiologie der Medizinischen Universität Innsbruck, emer

Stem cells are unique cell populations that retain the capability of either self-renewal in nearly infinite cell divisions or to differentiate into somatic cell types (asymmetric cell division). In this webinar the challenges in stem cell culture techniques, the types and characteristics of stem cells, and their applications and future perspectives will be discussed.

PELOAcademy: Clinical Potential of MSC-EVs and Translational Challenges

Prof. Dr. rer. nat. Bernd Giebel, Universitätsklinikum Essen (AöR), Institut für Transfusionsmedizin

Human mesenchymal stromal cells (MSCs) are a therapeutically relevant, heterogenous cell entity with immunomodulatory and pro-regenerative potentials. Apparently, MSCs mediate a huge proportion of their therapeutic effects via extracellular vesicles (EVs). Connected to several advantages in using cell-free products for the therapeutic setting, MSC-EVs emerged as promising novel therapeutic agent for various diseases, including graft-versus-host disease (GvHD), ischemic stroke, COVID-19, and sepsis. Learn more about a lentiviral, hTERT-based immortalization strategy, EVs and immortalized MSCs (ciMSCs).

Considerations & Testing: Using Primary Hepatocytes in 2D and 3D Cell Culture

Presented by Dr. Rafal P. Witek, a KOL in the hepatocyte sector, hosted by our partner AnaBios

Review selection criteria and sources of variabilities including donor variabilities, process variabilities, and functional stability that impact the performance of cryopreserved primary hepatocytes when used in In Vitro cell culture. Different criteria for 2D and 3D use will be covered to enable participants to understand how to select the best-performing primary hepatocyte lots for their studies. We cover also best practices when handling primary hepatocytes during storage, after thawing, during plating, and during 3D aggregation to overcome challenges related to data reproducibility and variability.

MSCs and Exosomes Therapeutics: Lessons Learned and a Promising Future

Presented by Kevin Hicok, KCH-Cell-Tx Consulting
and hosted by Rob McCarthy, VitaCyte

Clinical research explored the use of mesenchymal stem cells (MSCs) to improve islet engraftment or suppress the immune response to allo-islets. The webinar will address the questions you may have about MSCs such as: what tissues contain MSCs and how are they isolated? How do they work? What is the status of MSCs as the primary or supplementary cell therapy?

PELOAcademy | Brain organoids: A versatile 3D tool to study human neurological development and disease

Presented by Dr. Insa S. Schroeder, GSI Helmholtzzentrum für Schwerionenforschung Darmstadt, Germany

Brain organoids, derived from human pluripotent stem cells, revolutionize neuroscience.  The lecture introduces organoids and covers generation techniques, region-specific specialization, and their role in modeling neurological diseases. Explore their potential for disease research, drug development, ethical considerations, and their ability to mimic human brain development.

EMERGE Episode 15 | Analysis of Quantitative MS-based Proteomics Experiments using MSstats and MSstatsTMT”

Presented by Devon Kohler, Khoury College of Computer Sciences at Northeastern University, USA and ReSyn Biosciences, South Africa

In this webinar we will review the core workflow and methods behind MSstats and its extensions, highlighting critical choices that need to be made in each step of the analysis. We will review how different analysis choices affect the final protein-level conclusions made on the experiment and discuss how to avoid potential analysis pitfalls.

Certificates of Analysis for Tissue Dissociation Enzymes: Practical Utility

Presented Robert McCarthy, VitaCyte, USA

Enzyme suppliers provide Certificates of Analysis (CoAs) for each lot of product purchased by the customer. The primary enzyme manufacturer or the companies re-selling the manufacturer’s product use these CoAs to report the results of quality testing and acceptance criteria used to release the product for sale. The specification limits set internally by the manufacturer are guided by customer feedback or by internal decisions to ensure the majority of lots pass specifications.

PELOAcademy: Why the Best Suitable Media is Important for Exosome Production

Presented by Hyungtaek Jeon, Xcell Therapeutics, Institute of Life Science, Korea

Mesenchymal stem cells (MSCs) are commonly used as a source of regenerative medicine due to their strong immunosuppressive and regenerative effects. The paracrine effect is one of the key mechanisms of MSC. Recently, it has been shown that extracellular vesicles (EVs), which include exosomes and microvesicles, orchestrate the principle mechanisms of action of MSCs after infusion.

Join: the discussion what is the ideal culture environment for the production of exosomes.

Expect: MSC-derived exosome productivity is compared using several media including CDM. Wound healing assay and angiogenesis assay were conducted to evaluate the characteristics of the produced exosomes.

PELOQuoi? Votre expert pour la culture cellulaire, PELOBiotech

Présenté par Dr. Gautier Arista, International Sales, PELOBiotech GmbH, Allemagne

Si vous ne connaissez pas PELOBiotech, joignez-vous à nous pour découvrir nos activités. Comme mise en bouche, sachez que nous sommes experts en culture cellulaire. Nous nous focalisons sur les cellules primaires et milieux de culture. Mais pas que, comme vous pourrez le constater en voyant notre large portfolio et autres services.

Vous connaissez déjà notre entreprise ? N’hésitez pas à venir dire bonjour, poser vos questions et découvrir nos plus récents partenaires et collaborateurs.

Le séminaire sera présenté par Dr. Gautier Arista, belge d’origine, travaillant maintenant à Munich chez PELOBiotech au niveau des ventes internationales. Vous pouvez vous enregistrer en suivant le lien ci-après.

language: French

PELOAcademy | Biomimicry at Nanoscale Level: a Step Forward Towards Organotypic Cell Studies

Presented by Prof. Matteo Santin, Director of the Centre for Regenerative Medicine and Devices, School of Applied Sciences, University of Brighton, UK

The lecture will show the ability of a novel class of biomimetic biomaterials substrates, PhenoDrive (Tissue Click Ltd, UK), to support the formation of 3D organ- and tissue-like structures while operating in traditional 2D cell cultures. The potential of these tissue engineering constructs in testing novel nanomedicines will be explored.